Cable Hill Partners’s Evoke Pharma EVOK Stock Holding History

Cable Hill Partners’s Portfolio EVOK Stock Details EVOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1	Closed	–	–	904
2017 Q4	$0	Buy	+1	New	+$415	﹤0.01%	956

Other funds holding EVOK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SOMRS

State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cable Hill Partners's EVOK Position: Q1 2018 in Review

Cable Hill Partners sold out of Evoke Pharma (EVOK) in Q1 2018, closing a stake of 1 share.

Cable Hill Partners first reported a position in EVOK in Q4 2017 and held it in 1 quarter. The position peaked at $0 in Q4 2017. 20 funds tracked by Wall St. Rank hold EVOK as of Q1 2018.

Cable Hill Partners reported no remaining Evoke Pharma position as of Q1 2018 after selling out during the quarter.
Cable Hill Partners sold 1 Evoke Pharma share in Q1 2018.
Cable Hill Partners first reported a position in Evoke Pharma in Q4 2017 and held it in 1 quarter.
Cable Hill Partners's Evoke Pharma position peaked at $0 in Q4 2017.
20 funds tracked by Wall St. Rank held Evoke Pharma as of Q1 2018.

Based on Cable Hill Partners's 13F filing for Q1 2018, filed 20 Apr 2018.